Literature DB >> 29693298

Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia.

Hideaki Yamakawa1,2, Hideya Kitamura1,2, Tamiko Takemura3, Satoshi Ikeda1, Akimasa Sekine1, Tomohisa Baba1, Tae Iwasawa4, Eri Hagiwara1, Shinji Sato5, Takashi Ogura1.   

Abstract

BACKGROUND AND
OBJECTIVE: Non-specific interstitial pneumonia (NSIP) has heterogeneous characteristics in terms of background, disease behaviour and prognosis. This study of fibrotic NSIP (f-NSIP) aimed to elucidate prognosis and disease behaviour from the viewpoint of clinical background and determine whether long-term change of pulmonary function could provide useful prognostic information.
METHODS: We analysed the medical records of 157 consecutive patients diagnosed with f-NSIP by surgical lung biopsy. Disease behaviour was categorized into two groups depending on long-term change of pulmonary function: progressive type (relative ≥5%/year decline in the slope of forced vital capacity and/or relative ≥7.5%/year decline in the slope of %diffusing capacity of lung carbon monoxide) or stable type. Predictors of disease behaviour and prognosis were determined using logistic and Cox regression models.
RESULTS: Our f-NSIP cohort included interstitial pneumonia with autoimmune features (IPAF) (36.9%), idiopathic (non-IPAF) (22.3%) and connective tissue disease-associated interstitial lung disease (40.8%). Multivariate analysis showed that idiopathic (non-IPAF) f-NSIP and progressive type disease were negative prognostic factors of mortality. Poor treatment response at 1 year was an independent predictor of progressive type disease, but was not related to survival. In terms of disease behaviour based on pulmonary function change, some patients with IPAF f-NSIP showed a progressive course.
CONCLUSION: Although an IPAF diagnosis was useful for identifying good prognosis in idiopathic f-NSIP, some idiopathic f-NSIP patients with or without IPAF showed progressive disease despite therapy. The definition of progressive type disease may be useful in clinical decision-making when determining therapy for f-NSIP.
© 2018 Asian Pacific Society of Respirology.

Entities:  

Keywords:  connective tissue disease; disease behaviour; interstitial pneumonia with autoimmune features; non-specific interstitial pneumonia; prognosis

Mesh:

Year:  2018        PMID: 29693298     DOI: 10.1111/resp.13313

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  4 in total

1.  Predictors of long-term prognosis in rheumatoid arthritis-related interstitial lung disease.

Authors:  Juan Chen; Yaqiong Chen; Dehao Liu; Yihua Lin; Lei Zhu; Shuli Song; Yudi Hu; Tao Liang; Yongliang Liu; Wei Liu; Lin Weng; Qiyuan Li; Shengxiang Ge; Dana P Ascherman
Journal:  Sci Rep       Date:  2022-06-08       Impact factor: 4.996

2.  Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria.

Authors:  Hideaki Yamakawa; Shintaro Sato; Emiri Tsumiyama; Tomotaka Nishizawa; Rie Kawabe; Tomohiro Oba; Teppei Kamikawa; Masanobu Horikoshi; Keiichi Akasaka; Masako Amano; Kazuyoshi Kuwano; Hidekazu Matsushima
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

Review 3.  Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.

Authors:  Hideaki Yamakawa; Yuko Toyoda; Tomohisa Baba; Tomoo Kishaba; Taiki Fukuda; Tamiko Takemura; Kazuyoshi Kuwano
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

4.  Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax.

Authors:  Hideaki Yamakawa; Yuta Tsukahara; Shintaro Sato; Hiroki Ohta; Gen Kida; Tomohiko Nakamura; Tomotaka Nishizawa; Rie Kawabe; Tomohiro Oba; Keiichi Akasaka; Masako Amano; Kazuyoshi Kuwano; Hiroki Sasaki; Tamiko Takemura; Hidekazu Matsushima
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-01-13       Impact factor: 0.670

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.